<DOC>
	<DOCNO>NCT02798952</DOCNO>
	<brief_summary>The purpose study ass long-term persistence immunity hepatitis B adolescent age 14-15 year vaccinate four dos Infanrix™-Hexa first two year life assess anamnestic response , immunogenicity , safety reactogenicity single challenge dose hepatitis B vaccine Engerix™-B Kinder .</brief_summary>
	<brief_title>A Study Evaluate Persistence Hepatitis B Antibodies , Immunogenicity Safety Engerix™-B Kinder Challenge Dose , Adolescents Vaccinated With Four Doses Infanrix™ Hexa During Infancy</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Hepatitis B Antibodies</mesh_term>
	<criteria>Subjects ' parent ( ) /Legally Acceptable Representative ( ) [ LAR ( ) ] , opinion investigator , comply requirement protocol . Written inform consent obtain parent ( ) /LAR ( ) subject prior performance study specific procedure . In addition inform consent sign parents/LAR ( ) , write informed assent subject sought . A male female age 14 15 time vaccination . Healthy subject establish medical history clinical examination enter study . Subjects document evidence previous vaccination four consecutive dos Infanrix hexa part routine vaccination Germany : three dos primary vaccination receive 9 month age one booster dose receive 11 18 month age . Female subject nonchildbearing potential may enrol study . Nonchildbearing potential define premenarche , current tubal ligation , hysterectomy ovariectomy . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Child care . Use investigational nonregistered product study vaccine period start 30 day dose study vaccine , plan use study period . Any medical condition judgment investigator would make intramuscular injection unsafe . Chronic administration immunosuppressant immunemodifying drug period start six month prior vaccine dose . For corticosteroid , mean prednisone ≥ 0.5 mg/kg/day , equivalent . Inhaled topical steroid allow . Administration longacting immunemodifying drug time study period . Planned administration/administration vaccine foreseen study protocol period start 30 day dose end 30 day dose HBV vaccine administration exception tetanus toxoid , reduce diphtheria toxoid acellular pertussis vaccine , give part routine vaccination practice . Seasonal pandemic influenza vaccine give time study , accord Summary Product Characteristics national recommendation . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product ( pharmaceutical product device ) . Evidence previous hepatitis B booster vaccination since administration fourth dose Infanrix hexa booster second year life . History intercurrent hepatitis B disease . Hepatitis B vaccination birth . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Family history congenital hereditary immunodeficiency . History reaction hypersensitivity likely exacerbate component vaccine . Major congenital defect serious chronic illness include thrombocytopenia bleeding disorder . History neurological disorder seizure . Acute disease and/or fever time enrolment . Fever define temperature ≥37.5°C oral , axillary tympanic route , ≥38.0°C rectal route . Subjects minor illness without fever may enrol discretion investigator . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Administration immunoglobulins and/or blood product period start 3 month dose study vaccine plan administration study period . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hepatitis B antibody</keyword>
	<keyword>Safety</keyword>
	<keyword>Challenge dose</keyword>
	<keyword>Persistence</keyword>
	<keyword>Engerix B Kinder</keyword>
	<keyword>Infanrix hexa</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Adolescents</keyword>
</DOC>